Magnano L, et al. - Researchers aimed at determining the life expectancy of follicular lymphoma (FL) patients according to their status at 30 months following the initiation of treatment in comparison with the sex and age-matched Spanish general population (relative survival; RS). Two hundred sixty-three consecutive FL patients in a 10-year period who needed therapy and were treated with rituximab-containing regimens comprised the training series. They validated the findings using an independent cohort of 693 FL patients from the Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO) group. As per outcomes, survival for FL patients treated with immunochemotherapy who were in complete response at 30 months was similar to a sex- and age-matched Spanish general population.